Save Studies Locally
We can save your selected studies locally in your browser to enhance your experience. This data stays on your device and is not shared with us or third parties. You can clear this data at any time.
By allowing this, you consent to storing study selections locally on your device. Privacy Policy
How to NavigateConnectDistinguished InvestigatorsConferencesEducationRLT ComponentsSponsorsTrial Stats
A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design
Description:
A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design
Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Contacts:
Arndt Vogel, Prof. Dr.vogel.arndt@mh-hannover.de
+49 511 5326 ext 760
Johanna Riedel, Dr.riedel.johanna@ikf-khnw.de
+49 7601 ext 4635
Government Study Link:
NCT04522544 - Click here to see study onClinicalTrials.gov
